Logo image
A review of the pharmacology and clinical application of alfaxalone in cats
Journal article   Open access   Peer reviewed

A review of the pharmacology and clinical application of alfaxalone in cats

Leon N. Warne, Thierry Beths, Ted Whittem, Jennifer E. Carter and Sebastien H. Bauquier
The veterinary journal (1997), Vol.203(2), pp.141-148
2015
PMID: 25582797
pdf
Published852.57 kBDownloadView
Open Access

Abstract

Life Sciences & Biomedicine Science & Technology Veterinary Sciences
Alfaxalone-2-hydroxpropyl-beta-cyclodextrin (alfaxalone-HPCD) was first marketed for veterinary use in Australia in 2001 and has since progressively became available throughout the world, including the USA, where in 2012 Food and Drug Administration (FDA) registration was granted. Despite the growing body of published works and increasing global availability of alfaxalone-HPCD, the accumulating evidence for its use in cats has not been thoroughly reviewed. The purpose of this review is: (1) to detail the pharmacokinetic properties of alfaxalone-HPCD in cats; (2) to assess the pharmacodynamic properties of alfaxalone-HPCD, including its cardiovascular, respiratory, central nervous system, neuromuscular, hepatic, renal, haematological, blood-biochemical, analgesic and endocrine effects; and (3) to consider the clinical application of alfaxalone-HPCD for sedation, induction and maintenance of anaesthesia in cats. Based on the published literature, alfaxalone-HPCD provides a good alternative to the existing intravenous anaesthetic options for healthy cats. (C) 2014 The Authors. Published by Elsevier Ltd.

Details

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.43 Anesthesiology
1.43.1642 Veterinary Anesthesia
Web Of Science research areas
Veterinary Sciences
ESI research areas
Plant & Animal Science
Logo image